CAJ | 학술논문

近年来，耐药结核患者逐渐增多，结核病治疗面临严峻挑战，新型抗结核药物研发愈加迫切，倍受关注。其中利福霉素类及其衍生物、氟喹诺酮类、新型大环内脂类等到中成药及其他药物已进入临床试验。该文就这些新型药物的作用机制、试验结果、临床疗效进行总结，尤其对利福布丁、莫西沙星、PA-824、TMC-207、利奈唑胺及PNU-100480进行重点介绍，以期为临床医师治疗结核病提供参考。
근년래，내약결핵환자축점증다，결핵병치료면림엄준도전，신형항결핵약물연발유가박절，배수관주。기중리복매소류급기연생물、불규낙동류、신형대배내지류등도중성약급기타약물이진입림상시험。해문취저사신형약물적작용궤제、시험결과、림상료효진행총결，우기대리복포정、막서사성、PA-824、TMC-207、리내서알급PNU-100480진행중점개소，이기위림상의사치료결핵병제공삼고。
The patients with drug-resistant TB in recent years are gradually increasing,tuberculosis treat-ment facing serious challenges,new anti-TB drugs research and development becomes more and more urgent and attention,The rifampicin mildew element class and its derivatives,fluoroquinolones, novel macrocyclic lipid until the Chinese patent drugs and other drugs have entered clinical trials .Here is to make a review of the mechanism of these novel agents,test results and clinical efficacy, especially for rifabutin,moxifloxacin, PA-824,TMC-207,linezolid and PNU-100480 introduced,in order for clinical treatment of tuberculosis and provide a reference.